Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia by Wang, Tao et al.
HAL Id: hal-02325905
https://hal.archives-ouvertes.fr/hal-02325905
Submitted on 22 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Combination of arsenic trioxide and Dasatinib: a new
strategy to treat Philadelphia chromosome-positive
acute lymphoblastic leukaemia
Tao Wang, Chunyan Cheng, Lijun Peng, Mengqing Gao, Mengping Xi, Sophie
Rousseaux, Saadi Khochbin, Jin Wang, Jianqing Mi
To cite this version:
Tao Wang, Chunyan Cheng, Lijun Peng, Mengqing Gao, Mengping Xi, et al.. Combination of arsenic
trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic
leukaemia. Journal of Cellular and Molecular Medicine, Wiley Open Access, 2018, 22 (3), pp.1614-
1626. ￿10.1111/jcmm.13436￿. ￿hal-02325905￿
Combination of arsenic trioxide and Dasatinib: a new strategy
to treat Philadelphia chromosome-positive acute lymphoblastic
leukaemia
Tao Wang a, # , Chunyan Cheng a, #, Lijun Peng a, Mengqing Gao a, Mengping Xi a,
Sophie Rousseaux b, Saadi Khochbin b, Jin Wang a, *, Jianqing Mi a, *
a State Key Laboratory for Medical Genomics and Department of Hematology, Shanghai Institute of Hematology, Collaborative
Innovation Center of Systems Biomedicine, Po^le Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital,
Shanghai Jiao Tong University School of Medicine, Shanghai, China
b CNRS UMR 5309, INSERM U1209, Institute for Advanced Biosciences, Universite Grenoble-Alpes, La Tronche, France
Received: July 12, 2017; Accepted: October 2, 2017
Abstract
Tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of Philadelphia chromosome-positive acute lymphoblastic leu-
kaemia (Ph+ ALL), one of the most common and aggressive forms of haematological malignancies. However, TKI resistance has remained
an unsolved issue. In this study, we investigate the impact of adding arsenic trioxide (ATO) on the action of Dasatinib, a second-generation
TKI, in Ph+ ALL. We show that ATO cooperates with Dasatinib in both TKI-sensitive and resistant Ph+ ALL cell lines to increase apoptosis
and we unravel the underlying mechanisms. Indeed, combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR
apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone. Additionally, ATO
and Dasatinib in combination repress the expression of several genes, which we previously showed to be associated with shorter survival
probability in ALL patients. Overall these data support the use of ATO in combination with Dasatinib as a novel therapeutic regimen for
Ph+ ALL patients.
Keywords: Philadelphia chromosome-positive acute lymphoblastic leukaemia arsenic trioxide tyrosine kinase
inhibitor apoptosis IRE1/JNK/PUMA pathway ATF4
Introduction
Ph+ ALL accounts for 20–30% of ALL. The BCR-ABL1 fusion protein,
which is encoded by the Ph chromosome, is the main driver of Ph+
ALL. The outcome of Ph+ ALL was very poor until the use of TKIs,
which target the kinase domain of the ABL1 moiety and block the cat-
alytic activity of BCR-ABL1. However, Ph+ ALL patients only exhibit a
transient response to a single-agent TKI. Thus, in clinical practice,
multi-agent chemotherapy needs to be added in combination with
TKIs. Nevertheless, resistance to this treatment has remained an
issue and is associated with a high mortality [1]. Accumulated studies
point to apoptosis incompetence as a main hallmark of TKI resistance
[2, 3]. Therefore, new strategies should be developed to restore the
apoptosis-inducing ability of TKIs.
ATO belongs to the arsenic compound family that has been
proved to be a potent molecule in fighting various cancers, includ-
ing several haematological malignancies [4, 5]. ATO combined with
all-trans retinoic acid (ATRA) increases the 50-month overall sur-
vival rate of acute promyelocytic leukaemia (APL) patients to 99%,
a result which is superior to ATRA combined with chemotherapy
[6, 7]. In addition, ATO combined with TKI showed synergistic anti-
leukaemia effect on chronic myelogenous leukaemia (CML), which
is also caused by BCR-ABL1 [8, 9]. Recently, we found that ATO
was able to rewire the response of mantle cell lymphoma (MCL) to
the proteasome inhibitor bortezomib [10]. Notably, in this context,
the apoptosis-promoting effects of ATO were identified as the most
#These authors contributed equally to this work.
*Correspondence to: Jianqing MI
E-mail: jianqingmi@shsmu.edu.cn
Jin WANG
E-mail: jinwang@shsmu.edu.cn
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
doi: 10.1111/jcmm.13436
J. Cell. Mol. Med. Vol 22, No 3, 2018 pp. 1614-1626
prominent effects within the anti-tumour activities of this molecule.
However, whether the combination of ATO with Dasatinib also
induces synergistic effects to trigger apoptosis in Ph+ ALL has not
yet been studied.
Apoptosis is a highly regulated process involving pro- and
anti-apoptosis factors that form complex networks driving cell
fate. Proteins of the Bcl-2, IAP and Flip families are critical regula-
tors of apoptosis. As a member of the Bcl-2 family, p53-up-regu-
lated modulator of apoptosis (PUMA) induces mitochondrial
dysfunction and caspase-dependent apoptosis by binding to anti-
apoptosis Bcl-2 family members and by relieving the pro-apopto-
sis proteins Bak/Bax [11]. PUMA is activated by a wide variety of
stress signals, such as Endoplasmic Reticulum (ER) stress, and
acts as an important mediator between ER stress and apoptosis
[12].
Unfolded protein response (UPR), which is mediated by three
axes, respectively PERK/eIF2a/ATF4, ATF6 and IRE1/XBP1s, is a con-
served protective process that counteracts ER stress. However, under
the condition of unrecoverable ER stress, UPR is also able to trigger
apoptosis.
We made the hypothesis that an interesting therapeutic strategy
would be to induce UPR pro-apoptotic pathways, while inhibiting its
cell protective activities. Here, we report that ATO in combination with
Dasatinib exerts significant synergistic pro-apoptotic effects, mainly
through activating the IRE1/JNK/PUMA cell apoptosis pathway, while
neutralizing the ATF4 cell survival pathway.
Strikingly, we further found that ATO plus Dasatinib synergistically
repress some genes whose expressions are associated with shorter
survival probabilities in ALL patients. These findings suggest that
ATO and Dasatinib combined together should be a promising thera-
peutic strategy for Ph+ ALL.
Materials and methods
Cell culture
Human Ph+ ALL cell lines SUP-B15 (TKI-resistant) and TOM-1(TKI-sen-
sitive) were cultured in IMDM (Gibco, Carlsbad, CA, USA) supplemented
with 20% foetal bovine serum (Gibco) at 37°C in a 5% CO2 atmo-
sphere.
Reagents and antibodies
DMSO was purchased from Sigma-Aldrich (St. Louis, MO, USA). Dasa-
tinib was purchased from Cell Signaling Technology (CST, Danvers, MA,
USA) and dissolved in DMSO. ATO was purchased from the First Affili-
ated Hospital of Harbin Medical University. c-ABL1, Bcl-2, Mcl-1, Noxa
and p53 antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA); b-actin antibody was bought from Sigma-
Aldrich; ERK, p-ERK, STAT5, p-STAT5, PI3K, p-PI3K, AKT, p-AKT, cas-
pase-9, caspase-3, PARP, XIAP, Survivin, Bcl-w, Bik, Bak, Bad, PUMA,
Bid, p21, JNK, p-JNK, p-ATF-2, p-JUN, IRE1, ASK1 and ATF4 antibodies
were purchased from CST; TRAF2 antibody was purchased from
ABclonal Biotechnology (Wuhan, Hubei, China); PML and ATF6 were
purchased from Abcam (Cambridge, MA, USA).
Cell viability assay
5 9 104 cells were seeded in 96-well plates. After treatment with ATO
and/or Dasatinib for 24, 36 or 48 hrs, 10 ll CCK8 (Dojindo Laborato-
ries, Kumamoto, Japan) was added to each well and incubated for
another 1.5–3 hrs at 37°C. Absorbance of the samples was measured
against a background control at 450 nm with a reference wavelength of
600 nm.
Analysis for synergy
The Combination Index (CI) of ATO and Dasatinib was calculated
using Calcusyn (Great Shelford, Cambridge, UK). CI < 1, CI = 1 and
CI > 1 indicated synergism, additive and antagonism effect, respec-
tively [13].
Western blot analysis
Total cell lysates were extracted using RIPA lysis buffer containing
19 cocktail inhibitor and 1 mM PMSF. Equal amounts of total proteins
were separated by 7.5–15% SDS-PAGEs and transferred to PVDF mem-
branes. After being blocked with 5% BSA for 1 hr at room temperature
(RT), each membrane was incubated overnight at 4°C with the primary
antibodies. After washing three times with 1 9 TBST, each membrane
was incubated with HRP-goat-anti-mouse IgG or anti-rabbit IgG (CST)
as secondary antibody for 1 hr at 4°C. The expressions of the proteins
of interest were detected by enhanced chemiluminescence kits (Milli-
pore, Billerica, MA, USA).
Co-immunoprecipitation (Co-IP)
Total cell lysates were extracted using lysis buffer [50 mM HEPES (pH
7.4), 150 mM NaCl, 2 mM CaCl2, 0.5% NP-40, 5% glycerol] containing
19 cocktail inhibitor and 1 mM PMSF for 30 min on ice and cen-
trifuged at 12,0009 g for 15 min at 4°C. The supernatants were col-
lected and incubated with protein A/G agarose beads (Santa Cruz) for
2 hrs at 4°C for pre-clear and further incubated with anti-IRE1 antibod-
ies overnight at 4°C with constant rotation for immunoprecipitation.
Subsequently, protein A/G agarose beads were added, and the mixture
was incubated for another 2 hrs at 4°C. Then, the beads were washed
six times with washing buffer [50 mM HEPES (pH 7.4), 150 mM NaCl,
2 mM CaCl2, 0.5% NP-40], followed by boiling with 25 ll 2 9 SDS-
PAGE loading buffer for 5 min. Then, the samples were centrifuged at
12,0009 g for 30 seconds (s) with the supernatants collected and
stored at 80°C.
Real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA,
USA), and the cDNA was obtained using HieffTM First Strand cDNA
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Synthesis Kit (YEASEN, Shanghai, China). Real-time PCR assay was
performed using HieffTM qPCR SYBR Green Master Mix (Low Rox
Plus) (YEASEN). The primers were as follows: GAPDH (Forward:
GAAGGTGAAGGTCGGAGTC, Reverse: GAAGATGGTGATGGGATTTC);
AGPS (Forward: TTAGTGGCATGGGTTTACCAAC, Reverse: CTCGATCATCT
GCCTCTTGTG); CDK6 (Forward: CCAGATGGCTCTAACCTCAGT, Reverse:
AACTTCCACGAAAAAGAGGCTT); ATAD2 (Forward: AGGCTCCATTGGAAA
AACCT, Reverse: CCTGCGGAAGATAATCGGTA); ARPP19 (Forward: AAG
GAAACGGTTGCAGAAAGG, Reverse: GGAGTGGGAATGTGGTCACC); SC4
MOL (Forward: TGCCTTTGATTTGTGGAACCTATT, Reverse: GTGCCAAGT
ATCTTCAATGACTGC); ACSL1 (Forward: CGACGAGCCCTTGGTGTATTT,
Reverse: GGTTTCCGAGAGCCTAAACAA); IGFBP7 (Forward: CGAGCAAGG
TCCTTCCATAGT, Reverse: GGTGTCGGGATTCCGATGAC); STARD4 (For-
ward: AGAAGGGCTTTTATCTTGTGGA, Reverse: CCAACCACAGGGATGGTT
AT). Amplifications were performed in a 7500 Real-time PCR System
(Applied Biosystems, Foster City, CA, USA).
Preparation of lentiviral expression vectors
pLVX-shRNA2 vector was purchased from Clontech Laboratories
(Mountain View, CA, USA). Recombinant lentiviral shPUMA (with a tar-
get sequence of 50-CGTGTGACCACTGGCATTCAT-30) [14], shIRE1-1
(with a target sequence of 50-GAGAAGATGATTGCGATGGAT-30),
shIRE1-2 (with a target sequence of 50-GAAATACTCTACCAGCCTCTA-30)
[15], shATF4-1 (with a target sequence of 50-GCCTAGGTCTCTTAGATG
ATT-30) and shATF4-2 (with a target sequence of 50-GCCAAGCACTTC
AAACCTCAT-30) were constructed according to the manufacturer’s
instructions.
pLVX-IRES-Puro vector was also purchased from Clontech
Laboratories. cDNA of JNK1-a2 and JNK1-b1 was amplified by PCR
and cloned into pLVX-IRES-Puro vectors. The kinase mutants of
JNK1-a2 and JNK1-b1 (JNK1-a2-M and JNK1-b1-M) were constructed
by a Fast Mutagenesis System (TransGen Biotech, Beijing, China).
The primers were as follows: Forward 50-ACGAGTTTTATGATGGCGC
CTGCTGTAGTGACT-30; Reverse 50-GCAGGCGCCATCATAAAACTCGTTCC
TGCAGTC-30.
Construction of knockdown or overexpression
cell lines
The retroviral supernatants from HEK293T cells produced by co-
transfection of pLVX-shRNA2/pLVX-IRES-Puro, pMD2.G (Addgene,
Cambridge, MA, USA) and psPAX2 (Addgene) were filtered with a
0.22 lm Sterile Milles Filter Unit (Millipore). The filtrates were then
used to re-suspend SUP-B15 cells, centrifuged at 12009 g for
90 min and incubated for another 24 hrs at 37°C. Cells were infected
twice and selected with puromycin (Sigma-Aldrich, from 0.5 lg/ml to
4 lg/mL).
Apoptosis assays
1 9 105 cells were washed with 1 9 PBS and re-suspended in 200 lL
staining solution containing 2 lL of Annexin V–FITC and 2 lL of
20 lg/mL PI (FITC-Annexin V staining kit, Clontech). Flow cytometry
was performed to analyse 1 9 104 cells. All data were collected, stored
and analysed by FlowJo (TreeStar).
Statistical analyses
Data are expressed as the mean  S.E.M. Significance was calculated
using Student’s t-test. A two-tailed value of P < 0.05 was considered to
be significant.
Results
Combination of ATO and Dasatinib exhibit
significant synergistic adverse effects on the
viability of Ph+ ALL cell lines
To detect the effects of ATO and Dasatinib on cell viability, we firstly
treated Ph+ ALL cell lines SUP-B15 and TOM-1 with ATO or Dasatinib
for 24, 36 and 48 hrs, respectively (Fig. 1A). We found that TOM-1
cells were more sensitive to Dasatinib than SUP-B15 cells. These
results are in agreement with a previous report showing that SUP-B15
cells were resistant to TKI, while TOM-1 cells were not [2]. Then,
increasing concentrations of ATO and Dasatinib were used to treat
SUP-B15 and TOM-1 cells for different time periods (Fig. 1B). As a
result, we observed that ATO plus Dasatinib was more effective in
affecting cell viability than each drug used alone in both SUP-B15 and
TOM-1 cells, treated during either 36 or 48 hrs. Also, the Combination
Index (CI) was less than one under all the used drug concentrations,
suggesting that ATO and Dasatinib have synergistic effects (Table S1).
ATO along with Dasatinib in Ph+ ALL cell lines
neither degrade BCR-ABL1 nor synergistically
inhibit the three main downstream pathways of
BCR-ABL1
Previous research demonstrated that ATO at the concentration of 1 or
2 lΜ induces the degradation of BCR-ABL1 in CML-blast crisis cell
line, K562 [16]. We indeed found that a higher concentration of ATO
(over 4 lΜ) could down-regulate BCR-ABL1 in SUP-B15 (Fig. S1).
However, we also observed that a lower concentration of ATO, used
alone or combined with Dasatinib, has no effect on BCR-ABL1 degra-
dation (Figs S1 and S2). In comparison, the expressions of PML
(a classical target protein of ATO) in SUP-B15 or TOM-1 and of
BCR-ABL1 in K562 were both remarkably down-regulated by lower
concentrations of ATO (Fig. S2). This observation suggested that the
synergistic effects found here on cell viability using ATO and Dasa-
tinib are mainly independent from the degradation of BCR-ABL1.
The oncogenic activity of BCR-ABL1 relies on its three main
downstream pathways: Ras/MAPK (ERK), JAK/STAT5 and PI3K/AKT.
Here, we observed that JAK/STAT5 and ERK are inhibited by Dasa-
tinib, whereas PI3K/AKT is not. More importantly, no synergistic inhi-
bitory effect of ATO and Dasatinib was detected on the activity of
ERK, JAK/STAT5 or PI3K/AKT (Fig. S3). This suggested that the syn-
ergistic effects of ATO and Dasatinib on cell viability did not rely much
on BCR-ABL1 and on its three main downstream pathways.
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ATO and Dasatinib used in combination induce a
higher level of apoptosis in Ph+ ALL cell lines
than ATO or Dasatinib used alone
To clarify the mechanism underlying the synergistic actions of ATO
and Dasatinib, we measured cell apoptosis after ATO and/or Dasatinib
treatments. Our findings were that: (i) the single-agent Dasatinib
induces apoptosis in TOM-1 cells but not in SUP-B15 cells, further
confirming that SUP-B15 cells are resistant to TKI; (ii) ATO induces
apoptosis both in SUP-B15 and TOM-1 cells; and more importantly
(iii) the combination of ATO and Dasatinib induces a much higher
level of apoptosis (Fig. 2A). In addition, analysing the cleavage of
apoptosis-related proteins caspase-9, 3 and PARP suggests that the
combination of ATO plus Dasatinib induces apoptosis through the
caspase pathway (Fig. 2B).
ATO and Dasatinib combined together strongly
up-regulate the expression of the pro-apoptotic
protein PUMA
To further elucidate how ATO plus Dasatinib triggered apoptosis, we
detected the expression of several apoptosis-related proteins of the
BCL-2, IAP and Flip families. The most important change was the
expression of PUMA, which was up-regulated by the single-agent
ATO and increased dramatically after the ATO plus Dasatinib combi-
nation treatment (Figs 3A and S4). Short hairpin RNAs (shRNA) were
then used to down-regulate PUMA in SUP-B15 cells (Fig. 3B). Conse-
quently, in PUMA knock-down cells, we observed a significant
decrease in apoptosis, which was associated with lower levels of acti-
vated caspase-9, 3 and PARP (Figs 3C and D). Taken together, these
findings demonstrate that the apoptosis induced by ATO plus Dasa-
tinib is PUMA-dependent.
The activation of the JNK pathway is responsible
for PUMA up-regulation as well as for ATO plus
Dasatinib-induced apoptosis
PUMA is known to be regulated by p53, c-myc, JNK and other fac-
tors. In this study, p53 and p21, a main downstream target of p53,
were down-regulated by Dasatinib, both in SUP-B15 and TOM-1
cells. However, after the ATO plus Dasatinib combination treatment,
the expressions of p53 and p21 were down-regulated similarly as
after single-agent Dasatinib in TOM-1 cells, and no significant
differences were detected in SUP-B15 cells. In addition, although
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c-myc was down-regulated by ATO and/or Dasatinib, its regulation
modes were quite different from PUMA (Fig. S5). On the contrary,
JNK was significantly activated in cells receiving the combination
treatment group, compared to each drug used alone. Additionally,
JUN and ATF-2, the two main downstream targets of JNK, were
also activated by the combination of ATO and Dasatinib (Fig. 4A).
These results suggest that PUMA is activated by JNK in our model
system.
More interestingly, we also found that PUMA, JUN and ATF-2 are
activated by a single-agent ATO in both cell lines, whereas JNK was
only activated in TOM-1, and not in SUP-B15. To explain this observa-
tion, SUP-B15 cells were treated with ATO for 0, 3, 6, 12 and 24 hrs,
respectively. We observed the following: (i) JNK was activated after
3 hrs of ATO treatment and then was rapidly inactivated; (ii) ATF-2
was activated by ATO with a peak at 6 hrs; and (iii) PUMA began to
be activated after 6 hrs of ATO treatment with a peak at 12 hrs
(Fig. S6). These results implied that the JNK pathway was only acti-
vated temporarily by the single-agent ATO in SUP-B15. Nevertheless,
under both ATO and Dasatinib treatments, the JNK pathway was sta-
bly activated.
As previously reported, the transient activation of JNK is involved
in cell survival, while persistent activation induced cell apoptosis [17].
Next, we explored whether the activation of JNK played an important
role in PUMA up-regulation and apoptosis in SUP-B15. To this aim,
we over-expressed a kinase-dead mutant of JNK that acts as a domi-
nant negative to inactivate the endogenous JNK. There are three inde-
pendent JNK genes, namely, JNK1, 2 and 3. JNK1 and JNK2 are
widely expressed, while JNK30s expression is predominantly
restricted to the brain, heart and testis. Studies suggest that the acti-
vation of JNK1 may induce apoptosis, whereas JNK2 inhibits it [18,
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19]. At least four alternatively spliced transcript variants of JNK1
exist, including two short JNK1 isoforms (JNK1-a1 and JNK1-b1) and
two long JNK1 isoforms (JNK1-a2 and JNK1-b2). In this study,
kinase-mutated JNK1-a2 (JNK1-a2-M) and JNK1-b1 (JNK1-b1-M)
were stably transfected into SUP-B15 cells. As a result, the JNK activ-
ity was reduced significantly in both JNK1-a2-M and JNK1-b1-M
transfected cells compared with control cells (NC) (Fig. 4B). More
remarkably, apoptosis was decreased in both JNK1-a2-M and JNK1-
b1-M cells, as well as the expression of PUMA and the cleavages of
caspase-9, 3, PARP (Figs. 4C and D). Collectively, these results indi-
cated that JNK1 plays a key role in PUMA up-regulation and in the
apoptosis induced by ATO plus Dasatinib.
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IRE1 activates JNK and plays a pivotal role in
the combination of ATO and Dasatinib treatment
effects
JNK is known to be activated by ASK1/2, which is recruited and acti-
vated by IRE1 through its binding to TRAF2 during ER stress [20].
We discovered a clear interaction between IRE1 and both ASK1 and
TRAF2 in the cells treated by the combination ATO plus Dasatinib in
SUP-B15 as well as in TOM-1 cells (Fig. 5A). shRNAs were then used
to stably knock-down IRE1 (shNC, shIRE1-1 and shIRE1-2) in SUP-
B15 (Fig. 5B). We found that the knockdown of IRE1 induces a signif-
icant decrease of the apoptosis triggered by ATO plus Dasatinib and
prevents the activation of JNK and the cleavage of caspase-9,3 and
PARP (Figs. 5C and D). Collectively, these results suggested that the
combination of ATO and Dasatinib activates JNK to induce apoptosis
through the UPR axis IRE1.
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ATF4 plays a protective role in cell apoptosis
As we mentioned above, in addition to IRE1/XBP1s, there are two
other main UPR axes: PERK/eIF2a/ATF4 and ATF6, the expression of
which we also detected after ATO and/or Dasatinib treatment. We
observed that ATF4 was up-regulated by ATO, but showed no
increase when ATO was combined with Dasatinib in both SUP-B15
and TOM-1 cell lines (Fig. 6A). Under the same conditions, ATF6 did
not change significantly (data not shown). As ATF4 can either pro-
mote cell survival or induce cell apoptosis, we decided to further
explore the exact role ATF4 in our model systems. shRNAs were used
to stably knock-down ATF4 (shNC, shATF4-1 and shATF4-2) in SUP-
B15 cells (Fig. 6B). The knockdown of ATF4 significantly increased
apoptosis, as well as the cleavage of caspase-9,3 and PARP triggered
by ATO (Fig. 6C and D). This suggested that, although ATO may pro-
tect cells from apoptosis by up-regulating ATF4, this protective effect
could be abolished when ATO and Dasatinib are used in combination.
Collectively, these results demonstrate that the combination of
ATO and Dasatinib synergistically induces cell apoptosis in Ph+ ALL
cell lines both by activating the IRE1-JNK-PUMA apoptosis pathway
and abolishing the ATF4-induced cell survival pathway.
ATO and Dasatinib synergistically regulate genes
associated with shorter survival in ALL patients
Previously, we defined a six-gene signature identifying aggressive
and treatment-resistant ALL in children and adults (in our work this
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group of ALL was named ‘P3’). This situation enabled us to perform a
supervised transcriptomic analysis to look for genes differentially
expressed between these aggressive ‘P3’ ALL and ALLs associated
with higher survival probabilities that we named “P1&2” [21]
(Fig. S7A). Moreover, following this approach we discovered that a
subset of ‘P1&2’ ALL displayed a general transcriptome which was
similar to the ‘P3’ group of aggressive ALL, although their survival
probabilities remained higher. This subset of ALL was called P1&2
‘P3-like’ (Fig. S7B). Based on the hypothesis that the differences in
gene expression between P3 and P1&2 ‘P3-like’ ALL should identify
genes whose activation would be directly related to the aggressive-
ness of the ALL, we compared the transcriptomes of these two sub-
sets of ALL. This approach led to the identification of a group of 27
genes, which are particularly up-regulated in P3 ALL (Table S2) and
are hence good candidates to be drivers of the aggressive nature of
these malignancies.
Here, we took advantage of these findings to monitor the expres-
sion of these 27 genes after ATO and/or Dasatinib treatments, with
the findings that: (i) in TKI-resistant SUP-B15 cells, ACSL1 was
up-regulated by ATO, but reversed by ATO plus Dasatinib; AGPS,
ARPP19 and IGFBP7 were up-regulated by Dasatinib, but reversed
by ATO plus Dasatinib; CDK6, SC4MOL and STARD4 were down-
regulated by ATO or ATO plus Dasatinib (Fig. 7A). (ii) in TKI-sensitive
TOM-1 cells, ACSL1 and IGFBP7 were similarly regulated as in
SUP-B15 cells; ARPP19 and ATAD2 were down-regulated by ATO
and further down-regulated by ATO plus Dasatinib, but not by
single-agent Dasatinib (Fig. 7B).
Taken together, these results lead to the following conclu-
sions: (i) ATO and Dasatinib could synergistically down-regulate
some genes associated with particularly poor prognosis in ALL;
(ii) the inability of Dasatinib to down-regulate ATAD2 in TKI-resis-
tant SUP-B15 cells may partly account for TKI resistance, sug-
gesting that specifically targeting ATAD2 may improve the
outcome of TKI-resistant patients; (iii) the regulation of AGPS,
CDK6, SC4MOL and STARD4 by ATO plus Dasatinib in SUP-B15
cells may also account for the observed strong synergistic effect
of ATO and Dasatinib used in combination in treating TKI-resis-
tant Ph+ ALL.
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Fig. 7 ATO combined with Dasatinib synergistically regulates some genes associated with shorter survival in ALL. (A) ACSL1, AGPS, ARPP19,
IGFBP7, CDK6, SC4MOL and STARD4 were detected by real-time PCR in SUP-B15 cells after a 24-hr treatment with ATO and/or Dasatinib.
(B) ACSL1, IGFBP7, ARPP19 and ATAD2 were detected by real-time PCR in TOM-1 cells after a 24-hr treatment with ATO and/or Dasatinib. Bars
represent the mean  S.E.M, n = 3. *P < 0.05; **P < 0.01; ***P < 0.001.
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Discussion
TKI resistance is a life-threatening problem in Ph+ ALL patients. In the
present study, we demonstrate that a combination of ATO and Dasa-
tinib is extremely effective in targeting Ph+ ALL cells.
We demonstrate that ATO combined with Dasatinib trigger apop-
tosis by simultaneously activating the IRE1/JNK/PUMA apoptosis
pathway and inhibiting the ATF4 survival pathway. IRE1 is an ER
transmembrane protein possessing both Ser/Thr kinase and endori-
bonuclease (RNase) activities. Upon ER stress, the oligomerized IRE1
becomes autophosphorylated, which activates its RNase activity lead-
ing to the cleavage of XBP1 mRNA. Spliced XBP1 encodes transcrip-
tional factors, XBP1s, which enhance the ER protein folding capacity
and ER-induced protein degradation to alleviate ER stress. However,
when ER stress is unrecoverable, IRE1 also causes endonucleolytic
decay of some ER-localized mRNAs, such as GRP78, to trigger apop-
tosis [22, 23]. Another study further confirmed that pseudokinase-
activated IRE1 could also cleave the XBP1 mRNA, but not trigger
apoptosis, suggesting that phosphorylation of IRE1 is crucial for
IRE1-induced apoptosis [22]. This is in agreement with the finding
that IRE1 can form a complex with TRAF2 and ASK1, which activates
ASK1/JNK signalling pathway to trigger cell apoptosis [24]. In the
present work, we also observe that ATO plus Dasatinib promotes the
formation of IRE1-TRAF2-ASK1 complex to trigger apoptosis. How-
ever, the relationship between IRE1-dependent mRNA decay and acti-
vation of the ASK1/JNK apoptosis pathway needs to be further
investigated.
ATF4 is a cAMP response element-binding transcription factor.
Translation of ATF4 is induced by stress signals including ER
stress, amino acid deprivation, anoxia/hypoxia and oxidative stress
through phosphorylation of eIF2a. ATF4 protects cells against
adverse conditions through activating genes whose product func-
tion is involved in amino acid import and metabolism, oxidative
stress response and protein secretion [25]. In addition, ATF4 can
directly target Mcl-1, an anti-apoptosis member of the Bcl-2 fam-
ily, or genes implicated in autophagy, to protect cells from apop-
tosis [26, 27]. However, ATF4 can also trigger apoptosis through
targeting genes involved in protein synthesis, which cause ATP
depletion and oxidative stress [28].
The precise mechanism by which ATF4 switches from anti-apop-
tosis to pro-apoptosis activities has not been studied. Armstrong
reported that transcriptional activation of ATF4 mediates ER stress-
induced cell death [29]. In the present work, we found that ATO was
up-regulated ATF4 at the protein level, but not at the mRNA level (data
not shown), showing that the transcriptional activity of ATF4 was not
affected by ATO. Meanwhile, we also observed that ATF4 protected
cells from apoptosis. Thus, it seems that some transcription factors,
by regulating the transcriptional activation of ATF4, may work as
‘switches’ between anti-apoptosis and pro-apoptosis, a hypothesis
that needs to be further demonstrated.
The limitation of this work is that we did not focus on the T315I
mutation of BCR-ABL1, one of the main mechanisms of resistance to
TKIs. Future directions include the construction of a T315I-mutated
SUP-B15 cell line, using the CRISPR/CAS9 gene editing technology,
in which we would test the effectiveness of ATO plus Dasatinib. How-
ever, it is possible to predict that the combination of ATO and Dasa-
tinib would not be effective in treating T315I mutation, as Dasatinib
does not work on T315I mutation. A third-generation TKI, Ponatinib,
which can inhibit the activity of T315I mutated BCR-ABL1, might be
alternatively combined with ATO.
Translating our findings into the clinics will also require testing the
safeness and effectiveness of ATO plus Dasatinib in pre-clinical studies.
We are presently establishing Ph+ ALL patient-derived xenograft (PDX)
models. If ATO plus Dasatinib works well in these animal models, it will
set a basis to explore this combination in clinical trials on Ph+ ALL
patients with relapse and/or resistance to current treatments. However,
whether this combination strategy could be used for maintenance (after
multi-agent chemotherapy) or even up-front treatments, needs to be
evaluated, depending on the outcome of the clinical trials.
In conclusion, we have identified a synergistic anti-leukaemia
effect of ATO and Dasatinib used together in two Ph+ ALL cell lines.
The underlying mechanism involves the promotion of cell apoptosis
through IRE1 and the concomitant neutralization of the ATF4-depen-
dent cell survival. As ATO and Dasatinib are both approved by the US
Food and Drug Administration, in the near future, these findings
should lead to pre-clinical and clinical studies to determine whether
the combination is safe and effective in Ph+ ALL patients.
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